Abstract：Objective: To explore the effect of budesonide combined with montelukast on interleukin-33 (IL-33), interleukin-17A (IL-17A) in peripheral blood and inflammatory factors in induced sputum of patients with bronchial asthma. Methods: 104 patients with bronchial asthma admitted to our hospital from March 2017 to March 2019 were randomly divided into control group and study group, 52 cases in each group. The control group was treated with Budesonide aerosol inhalation, while the study group was treated with budesonide and montelukast. The respiratory function, serum IL-33, IL-17A water of the two groups were compared before and after treatment. Levels of IL-5 and IFN-gamma in induced sputum were also measured. Results: Before treatment, there was no significant difference between the two groups in each index. After treatment, FEV1 and FEV1 / FVC ratio of the study group were (2.89 ± 0.84) L and (86.47 ± 7.62) %, respectively, which were significantly higher than those of the control group. The serum levels of IL-33 and IL-17A in the study group were (68.75 ± 8.42) ng / L and (4.02 ± 0.67) ng / L, respectively, which were significantly lower than those in the control group. The level of IL-5 in induced sputum of the study group was (71.52 ± 21.69) pg / mL, significantly lower than that of the control group, and the level of IFN - γ in induced sputum was (64.31 ± 16.83) pg / mL, significantly higher than that of the control group (P<0.05). Conclusion: Budesonide combined with montelukast in the treatment of bronchial asthma can significantly improve the level of inflammatory factors, reduce airway inflammation, improve respiratory function of patients, and is conducive to the improvement of clinical efficacy. The combined therapy is worthy of promotion and application.
徐青. 布地奈德联合孟鲁司特对支气管哮喘患者外周血IL-33 IL-17A及诱导痰炎性因子的影响[J]. 河北医学, 2020, 26(3): 362-365.
XU Qing. Effect of Budesonide Combined with Montelukast on IL-33 IL-17A and Induced Phlebitis in Peripheral Blood of Patients with Asthma. HeBei Med, 2020, 26(3): 362-365.
[1] 李文,宁君,申长清,等.孟鲁司特及布地奈德对支气管哮喘儿童氧化应激的影响[J].临床肺科杂志,2017,22(2):332~333. [2] 李小明.支气管哮喘患者外周血CD4+T、CD8+T、Th17、IL-17表达水平与肺功能的相关性研究[J].河北医科大学学报,2018,39(5):14~17,23. [3] Sareh Raeiszadeh Jahromi, P. A. Mahesh, B. S. Jayaraj, et al. Serum levels of IL-10, IL-17F and IL-33 in patients with asthma: a case-control study[J]. Journal of Asthma Research, 2014, 51(10):1004~1013. [4] 中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志,2016,39(9):675~697. [5] 孙妍.西替利嗪口服联合布地奈德吸入对小儿哮喘急性发作过程中免疫炎症反应的影响[J].海南医学院学报,2017,23(23):3271~3274. [6] C-H L, H-D W, J-J L, et al. Functional phenotype and its correlation with therapeutic response and inflammatory type of bronchoalveolar lavage fluid in feline lower airway disease[J]. Journal of Veterinary Internal Medicine, 2015, 29(1):88~96. [7] 张佳佳,胡赤军,周小勤,等.布地奈德联合孟鲁司特钠对支气管哮喘患儿细胞因子、免疫功能影响[J].现代生物医学进展,2017,17(3):159~162. [8] 彭锦芸,吴李勇,肖建宏,等.孟鲁司特钠片联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床研究[J].中国临床药理学杂志,2017,33(24):2559~2561. [9] 陈杰,张卓然,蔡志刚,等.IL-27对支气管哮喘患者血清干扰素γ、IL-33水平的影响[J].国际呼吸杂志,2014,34(5):321~324. [10] Rajanandh M G, Nageswari A D, Ilango K. Assessment of montelukast, doxofylline and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment a randomized trial[J]. Clinical Therapeutics, 2015, 37(2):418~426. [11] 陈长荣,邓静敏,龚臣,等.慢性持续期过敏性支气管哮喘外周血IL-17、IL-10与IL-4、IFN-γ失衡状态的研究[J].广西医科大学学报,2014,31(3):414~416. [12] Heinisch I V W M, Daigle I, Knpfli B, et al. CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils[J]. European Journal of Immunology, 2015, 30(12):3441~3446.
2020, Vol. 26 
冀公网安备13080202000677号